Trial Profile

A phase II study assessing the intracranial response to nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Brain metastases; Malignant melanoma
Focus Therapeutic Use
Acronyms ABC Trial

Most Recent Events

15 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2028.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
27 Mar 2018 Results (n=79) assessing efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with active melanoma brain metastases, were published in the Lancet Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com